#USA #Bridgewater #Insmed #PAH #TPIP

Insmed's Presentation at PVRI 2026 Congress

Insmed Incorporated, a leading global biopharmaceutical company, is set to make waves at the upcoming Pulmonary Vascular Research Institute (PVRI) Congress in Dublin, taking place from January 28 to February 1, 2026. This year, Insmed will present multiple abstracts that shed light on the promising implications of treprostinil palmitil inhalation powder (TPIP) for treating pulmonary arterial hypertension (PAH).

Key Presentations

Among the highlights will be the Phase 3 PALM-PAH study design, along with a compelling encore presentation of topline results from the previous Phase 2b study. In addition to these, a groundbreaking analysis utilizing Functional Respiratory Imaging and novel data demonstrating the pulmonary vasodilatory effects of TPIP in rat models will also be showcased.

Dr. Martina Flammer, Chief Medical Officer at Insmed, expressed excitement about the company’s strong presence at the congress. She stated, "We are pleased that TPIP will have a significant presence at this year's PVRI 2026 congress, reflecting the growing body of evidence supporting its potential to become the prostanoid of choice." These clinical data and findings serve as critical foundations as the company embarks on multiple Phase 3 programs, particularly the PALM-PAH study, aimed at improving outcomes for patients suffering from this serious condition.

Details of Presentations

The presentations will cover a range of essential topics, including:

• - Pulmonary Vasodilation with TPIP in Rat Isolated Perfused Lungs:

- Lead Author and Presenter: Tam Nguyen
- Moderated Poster Discussion: Robinson Suite, January 30, 2026, 15:10 – 16:15, Poster Board 41

• - Phase 3 Trial Study Design:

- Lead Author: Ekkehard Grünig
- Presenter: Raymond Benza
- Moderated Poster Discussion: Higgins Suite, January 31, 2026, 09:55 - 11:00, Poster Board 7

• - Insights from Functional Respiratory Imaging Analysis:

- Lead Author and Presenter: Ioana Preston
- Moderated Poster Discussion: Higgins Suite, January 31, 2026, 09:55 - 11:00, Poster Board 8

• - Encore Presentation of the Phase 2b Study:

- Lead Author: Ekkehard Grünig
- Presenter: Amy Boutet
- Moderated Poster Discussion: Higgins Suite, January 31, 2026, 09:55 - 11:00, Poster Board 6

Understanding TPIP and PAH

Treprostinil palmitil inhalation powder is an innovative inhalation therapy currently being evaluated for its once-daily application for patients suffering from PAH and other serious pulmonary disorders. This formulation is a prodrug that links treprostinil with a long carbon chain, enhancing its therapeutic potential. As the Phase 2b study demonstrated, TPIP is designed for ease of use with a capsule-based inhalation device, making it more accessible for patients.

PAH, a rare condition affecting approximately 35,000 individuals in the U.S. alone, leads to elevated blood pressure in lung arteries, with symptoms such as shortness of breath and fatigue. The untreated condition can be debilitating and often fatal, emphasizing the crucial need for effective treatments like TPIP.

Given that the adjuvant Phase 2b study involves a randomized, double-blind, multicenter approach with a total of 102 participants, it was meticulously crafted to assess the efficacy, safety, and pharmacokinetics of TPIP. Patients were closely monitored for changes in pulmonary vascular resistance, a crucial indicator for assessing treatment success.

About Insmed

Insmed is committed to making significant contributions to the biopharmaceutical landscape with a robust pipeline of investigational medicines and a focus on transforming the lives of patients facing severe illnesses. With headquarters in Bridgewater, New Jersey, Insmed is recognized for its dedication to employee satisfaction and innovative research.

As the company continues to unveil new therapies, their presentation at PVRI 2026 not only highlights significant advances in medical science but also underscores the potential for improved patient outcomes in the challenging realm of pulmonary diseases.

For further information or updates, visit Insmed’s official website or follow their social media channels.